Chemistry:Ziresovir

From HandWiki
Revision as of 11:09, 6 March 2023 by TextAI2 (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Medication
Ziresovir
Ziresovir.svg
Clinical data
Trade namesZiresovir
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H25N5O3S
Molar mass439.53 g·mol−1
3D model (JSmol)

Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.[1][2][3]

See also

References

  1. "Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor". Journal of Medicinal Chemistry 62 (13): 6003–6014. July 2019. doi:10.1021/acs.jmedchem.9b00654. PMID 31194544. 
  2. "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research 167: 45–67. July 2019. doi:10.1016/j.antiviral.2019.04.006. PMID 30974127. 
  3. Taylor, Nick Paul (7 April 2022). "ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data" (in en). https://www.fiercebiotech.com/biotech/arkbios-ex-roche-antiviral-hits-primary-goal-rsv-phase-3-sparking-race-regulator-and-wait.